M&A Deal Summary

Fulgent Acquires Inform Diagnostics

On April 18, 2022, Fulgent acquired life science company Inform Diagnostics from Avista Healthcare Partners for 170M USD

Acquisition Highlights
  • This is Fulgent’s 2nd transaction in the Life Science sector.
  • This is Fulgent’s largest (disclosed) transaction.
  • This is Fulgent’s 2nd transaction in the United States.
  • This is Fulgent’s 1st transaction in Texas.

M&A Deal Summary
Date 2022-04-18
Target Inform Diagnostics
Sector Life Science
Buyer(s) Fulgent
Sellers(s) Avista Healthcare Partners
Deal Type Add-on Acquisition
Deal Value 170M USD

Target

Inform Diagnostics

Irving, Texas, United States
Inform Diagnostics is a provider of anatomic pathology services primarily in the fields of gastroenterology, dermatology, hematology, breast health, and urology. The company's team of more than 90 distinguished expert subspecialists utilizes state-of-the-art pathology laboratories to serve more than 5,500 patients every day. Inform Diagnostics continuously improves diagnostic accuracy through consensus-based terminology and criteria, rigorous quality assurance, daily consensus conferences, extensive educational and training activities, and close relationships with clinical partners. Inform Diagnostics was formed in 1996 and is based in Irving, Texas.

Search 198,123 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Fulgent

Temple City, California, United States
Category Company
Founded 2011
Sector Life Science
Employees700
Revenue 421M USD (2020)
DESCRIPTION

Fulgent is a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health. Fulgent’s proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy, and competitive turnaround times. Combining next-generation sequencing with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service, and automated lab services. Fulgent was founded in 2011 and is based in Temple City, California.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Add-on Acquisition) 2 of 3
State (Texas) 1 of 1
Country (United States) 2 of 3
Year (2022) 1 of 2
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-08-09 CSI Laboratories

Alpharetta, Georgia, United States

CSI Laboratories provides a client- and patient-focused model of cancer diagnostic testing for pathologists, community hospitals and their patients. CSI Laboratories offers flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, molecular genetics, next-generation sequencing, and consultations to hematopathology and surgical pathology clients. CSI Laboratories was founded in 1997 and is based in Alpharetta, Georgia.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-11-07 Fulgent Pharma

Temple City, California, United States

Fulgent Pharma is an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments. Fulgent Pharma is based in Temple City, California.

Buy $100M

Seller(S) 1

SELLER

Avista Healthcare Partners

New York, New York, United States
Category Private Equity Firm
Founded 2005
PE ASSETS 6.0B USD
Size Mega
Type Sector Focused
DESCRIPTION

Avista Capital Partners is a private investment firm formed by a group of professionals with roots from DLJ Merchant Banking Partners. Avista makes controlling and minority investments in US based energy, healthcare, and media companies with revenues greater than $25 million. Typical transactions include leverage buyouts, build-ups, and growth capital financings. Avista Capital was formed in 2005 and is based in New York City with an additional office in Houston, Texas.

DEAL STATS #
Overall 30 of 30
Sector (Life Science) 7 of 7
Type (Add-on Acquisition) 15 of 15
State (Texas) 6 of 6
Country (United States) 24 of 24
Year (2022) 1 of 1
Size (of disclosed) 11 of 11
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-15 Probo Medical

Fishers, Indiana, United States

Probo Medical is a provider of equipment sales, part sales, equipment rentals, depot repair service, equipment installation and de-installation, and field-based repair services. Probo Medical was founded in 2014 and is based in Fishers, Indiana.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-08-23 WellSpring Consumer Healthcare

Sarasota, Florida, United States

WellSpring Consumer Healthcare is a marketer of over-the-counter and cosmetic brands in the skincare, feminine hygiene, and gastrointestinal care categories. WellSpring’s portfolio includes Bactine, Bonine, FDS, Emetrol, Micatin, Gelusil, Glaxal Base, Barriere, and K-Lyte. WellSpring Consumer Healthcare was founded in 1999 and is based in Sarasota, Florida.

Buy -
Mergr

Product

Company

Legal